BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 29745361)

  • 1. A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes.
    Daly LE; Prado CM; Ryan AM
    Proc Nutr Soc; 2018 May; 77(2):135-151. PubMed ID: 29745361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival.
    Ryan AM; Prado CM; Sullivan ES; Power DG; Daly LE
    Nutrition; 2019; 67-68():110539. PubMed ID: 31522087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial plasticity in cancer-related muscle wasting: potential approaches for its management.
    Vitorino R; Moreira-Gonçalves D; Ferreira R
    Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):226-33. PubMed ID: 25783794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis.
    Baracos VE; Reiman T; Mourtzakis M; Gioulbasanis I; Antoun S
    Am J Clin Nutr; 2010 Apr; 91(4):1133S-1137S. PubMed ID: 20164322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice.
    Ryan AM; Sullivan ES
    Proc Nutr Soc; 2021 Feb; 80(1):73-91. PubMed ID: 32981540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
    Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
    Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact.
    Prado CM; Cushen SJ; Orsso CE; Ryan AM
    Proc Nutr Soc; 2016 May; 75(2):188-98. PubMed ID: 26743210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
    Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
    Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
    Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of low muscle mass across the continuum of care: a narrative review.
    Prado CM; Purcell SA; Alish C; Pereira SL; Deutz NE; Heyland DK; Goodpaster BH; Tappenden KA; Heymsfield SB
    Ann Med; 2018 Dec; 50(8):675-693. PubMed ID: 30169116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
    Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
    Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study.
    da Rocha IMG; Marcadenti A; de Medeiros GOC; Bezerra RA; Rego JFM; Gonzalez MC; Fayh APT
    J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):445-454. PubMed ID: 30924270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
    Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
    [No Abstract]   [Full Text] [Related]  

  • 15. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?
    Prado CM; Sawyer MB; Ghosh S; Lieffers JR; Esfandiari N; Antoun S; Baracos VE
    Am J Clin Nutr; 2013 Oct; 98(4):1012-9. PubMed ID: 23966429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia.
    Di Sebastiano KM; Yang L; Zbuk K; Wong RK; Chow T; Koff D; Moran GR; Mourtzakis M
    Br J Nutr; 2013 Jan; 109(2):302-12. PubMed ID: 23021109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study.
    Emanuele E; Bertona M; Pareja-Galeano H; Fiuza-Luces C; Morales JS; Sanchis-Gomar F; Lucia A
    Neuro Endocrinol Lett; 2016 Jul; 37(3):213-216. PubMed ID: 27618596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cachexia and myopenia - Update on management strategies and the direction of future research for optimizing body composition in cancer - A narrative review.
    Pring ET; Malietzis G; Kennedy RH; Athanasiou T; Jenkins JT
    Cancer Treat Rev; 2018 Nov; 70():245-254. PubMed ID: 30321741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer.
    Daly LE; Ní Bhuachalla ÉB; Power DG; Cushen SJ; James K; Ryan AM
    J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):315-325. PubMed ID: 29318756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.